Year Founded
2024
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Bispecific T cell engager (BiTE)Bispecific antibodyTrispecific antibody

Candid Therapeutics General Information

Two T-cell engager antibodies (CND106 and CND261) have completed Phase 1 dose escalation studies with combined data in over 130 oncology patients, being repositioned for autoimmune indications

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States

Drug Pipeline

CND106
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Candid Therapeutics's pipeline data

Book a demo

Key Partnerships

Nona Biosciences, WuXi Biologics, Ab Studio, EpimAb Biotherapeutics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Candid Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Candid Therapeutics's complete valuation and funding history, request access »

Candid Therapeutics Investors

Foresite Capital
Investor Type: Venture Capital
Holding: Minority
Foresite Labs
Investor Type: Venture Capital
Holding: Minority
Two River
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »